



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

WEST et al.

Serial No.: 10/551,203

Filed: September 27, 2005

Art Unit: (not yet assigned)

Examiner: (not yet assigned)

Atty. Docket No.: 05-167-US

ALKALOID FORMULATIONS

Commissioner for Patents
MAIL STOP PETITION
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98. The items listed on the enclosed Form PTO-1449 may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. Enclosed is PTO Form 1449 (and a duplicate thereof).
2. Items listed on the enclosed Form PTO-1449
 - that are not in the English language:
 - For each of the following items, an English-language abstract is enclosed:
 - For each of the following items, a concise explanation of that item is incorporated in the specification of the above-identified application:

- For each of the following items, a corresponding U.S. or other English-language patent is enclosed or has been previously cited. Please consider the U.S. or other English-language patents in accordance with the procedure set forth in MPEP § 609.
- that are U.S. patents or publications, no copies are being provided in accordance with the Official Gazette Notice of August 5, 2003.

3. **Submission in Accordance with 37 CFR § 1.98(d).**

Any copy of the items listed on the enclosed Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in Application Serial No. [Ser. No.], filed [Date], of which the present application relies upon for an earlier filing date under 35 U.S.C. 120.

4. **Submission in Accordance with 37 CFR § 1.97(b).**

This Information Disclosure Statement is being filed

- With the application;
- Within three months of the filing date of a national application;
- Within three months of the date of entry of the national stage in an international application; or
- Before the mailing date of a first Office Action on the merits,

and NO FEE is due for consideration of this Information Disclosure Statement.

5. **Submission in Accordance with 37 CFR 1.97(c).**

This Information Disclosure Statement is being filed before the first mailing date of either

- A final action under § 1.113; or
- A notice of allowance under § 1.311.
- A fee is due for consideration of this Information Disclosure Statement and the fee is paid below; or
- This Information Disclosure Statement is accompanied by one of the certifications pursuant to 37 CFR § 1.97(e), and NO FEE is due for consideration of this Information Disclosure Statement.

6. **Submission in Accordance with 37 CFR 1.97(d).**

This Information Disclosure Statement is being filed after the mailing date of either

- A final action under § 1.113; or
- A notice of allowance under § 1.311,

whichever comes first, but before payment of the issue fee, and is accompanied by

- a. One of the certifications pursuant to 37 CFR § 1.97(e), which is set forth below;
- b. The attached petition requesting consideration of this Information Disclosure Statement; and
- c. The petition fee under 37 CFR § 1.17(i)(1), which is paid below.

7. **Certification Pursuant to 37 CFR 1.97(e).**

- The undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application not more than three months prior to the filing of this Information Disclosure Statement; or
- The undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

8. **Fee Payment Being Made.**

- Enclosed
 - \$180.00 fee for submission under 37 CFR § 1.97(c).
 - \$180.00 fee for submission under 37 CFR § 1.97(d).
- A check in the amount of \$[Amount] to cover the fee payment is enclosed.
- Charge the fee to Deposit Account No. 18-0582. A duplicate copy of this communication is attached.

- The Director is hereby authorized to charge payment of any additional fees associated with this Information Disclosure Statement or credit any overpayment to Deposit Account No. 18-0582. A duplicate copy of this communication is enclosed.

Respectfully submitted,



James G. Dilmore, Patent Agent
Reg. No. 51,618

REED SMITH LLP
P.O. Box 488
Pittsburgh, PA 15230-0488
(412) 288-3813

Agent for Applicants

Dated: June 29, 2006

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(MODIFIED) U.S. PATENT AND TRADEMARK OFFICE



ATTY. DOCKET NO.

05-167-US

SER. NO.

10/551,203

APPLICANT

WEST et al.

FILING DATE

September 27, 2005

GROUP

(Not yet assigned)

(37 CFR 1.98(b))

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No. ¹	Patent Number	Issue Date	Patentee	Class/Subclass	Filing Date
_____	_____	6384043	5/2002	Peyman et al.	_____	_____

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Document Number	Publication Date	Country or Patent Office	Class/Subclass	Translation Yes/No
_____	2004/014432	2/2004	WO	_____	_____
_____	2003/024429	3/2003	WO	_____	_____
_____	2003/024430	3/2003	WO	_____	_____
_____	JP 025-201858	8/1993	JP	_____	abstract only

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No. ¹	
_____	_____	_____

EXAMINER	DATE CONSIDERED
_____	_____

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.